849
A BLOOD-BASED BIOMARKER PANEL FOR NON-INVASIVE DIAGNOSIS OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Date
May 20, 2024
Tracks
Related Products
TARGETING SQLE REACTIVATES ANTITUMOR IMMUNITY AND RESCUES IMMUNE CHECKPOINT EFFICACY IN NON-ALCOHOLIC STEATOHEPATITIS-INDUCED HEPATOCELLULAR CARCINOMA
BACKGROUND: The LI-RADS (Liver Reporting and Data Systems) was created to standardize reporting of CT/MR imaging for liver masses in cirrhosis patients at risk of hepatocellular carcinoma (HCC)…
THE EFFECT OF GUT MICROBIOTA ON IMMUNE CHECKPOINT INHIBITORS IN THE TREATMENT OF PAN-CANCER AND NOVEL MICROBIAL BIOMARKERS FOR PREDICTING THERAPEUTIC RESPONSE
The gut microbiota is closely related to cancer patient response to immune checkpoint inhibitors (ICI). However, there are inconsistencies in species affecting ICI efficacy, whilst the role of non-bacterial microbes in immunotherapy remains elusive…
INTESTINAL TM6SF2 PROTECTS AGAINST NON-ALCOHOLIC STEATOHEPATITIS THROUGH GUT-LIVER AXIS
Background: Nonalcoholic steatohepatitis (NASH) is a major cause of liver-related morbidity, mortality, and the leading indication for liver transplant in the US. Fibrosis is the best predictor of clinical outcomes in NASH…
FAECALIBACTERIUM PRAUSNITZII INHIBITS GASTRIC CANCER AND ANTAGONIZES HELICOBACTER PYLORI COLONIZATION
BACKGROUND: The roles of probiotics in inhibiting gastric cancer (GC) and effecting _H. pylori_ infection are largely unclear. We identified _Faecalibacterium prausnitzii_ is depleted in GC. We aimed to evaluate the antitumorigenic function and molecular mechanism of _F…